| abstract |
The principle of the present invention is the use of a therapeutically or prophylactically effective amount of a bupropionic metabolite selected from the group consisting of (R, R) -2- (3-chlorophenyl) -2-hydroxy-3,5,5-trimethylmorpholinol, (S, S) - 2- (3-chlorophenyl) -2-hydroxy-3,5,5-trimethylmorpholinol, (R, R) -2- (t-butylamino) -1- (3-chlorophenyl) propan-1-ol, (R) S) -2- (t-butylamino) -1- (3-chlorophenyl) -propan-1-ol, (S, S) -2- (t-butylamino) -1- (3-chlorophenyl) -propane- 1-ol, (R) -1- (3-chlorophenyl) -2 - [(1,1-dimethylethanol) amino] -1-propanol and (S) -1- (3-chlorophenyl) -2 - [(1) , 1-dimethylethanol) amino] -1-propanone and pharmaceutically acceptable salts, solvates, hydrates and clathrates thereof for the manufacture of a medicament for the treatment or prevention of anxiety disorders. |